VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse — Axel Le Cesne (2024) | RDL Network
Axel Le Cesne, Sylvie Chabaud, O. Bouche, Nicolas Penel, Mehdi Brahmi, Maud Toulmonde, Emmanuelle Bompas, François Bertucci, L. Chaigneau, W. Lahlou, B. Landi, B. Verret, Clémence Hénon, Diane Pannier, Marc Pracht, Olivier Collard, Isabelle Laure Ray-Coquard, Séverine Metzger, David Pérol, Jean Yves Blay
Jean Yves Blay, Camille Schiffler, Olivier Bouché, Mehdi Brahmi, F. Duffaud, Maud Toulmonde, B. Landi, W. Lahlou, Diane Pannier, Emmanuelle Bompas, François Bertucci, L. Chaigneau, Olivier Collard, Marc Pracht, Clémence Hénon, I. Ray-Coquard, K Armoun, Sébastien Salas, Mariella Spalato Ceruso, Antoine Adenis, B. Verret, Nicolas Penel, Camille Moreau-Bachelard,
Discussion(0)
No comments yet. Be the first to comment.